Ferring Pharmaceuticals AS is taking a big leap into the forefront of the microbiome drug development space with the proposed acquisition of Rebiotix Inc.. The Swiss specialty pharma announced plans to buy Roseville, Minn.-based Rebiotix April 5 for an undisclosed sum, gaining a Phase III treatment for recurrent Clostridium difficile infection (CDI) that is a contender to be the first approved human microbiome product.
Rebiotix's RBX2660 is in Phase III testing for the prevention of recurrent CDI, and the company also has a pipeline...








